Look beyond the healthcare company's recent setbacks.

Sanofi (NASDAQ:SNY) is a French pharmaceutical firm that has been at the center of several analysts’ attention lately.

ASH Annual Meeting and Exposition leaves the oncology community buzzing over a series of late-breaking presentations that experts are calling 'unprecedented.' Major pharmaceutical developers such as ...

Regeneron Pharmaceuticals sees its Relative Strength Rating reach the 80-plus level.

The biotechnology sector is characterized by significant price swings, and Regeneron Pharmaceuticals is currently navigating one such period. Although the co ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial ...

The 23andMe Research Institute bought the company's assets for $305 million, scotching a proposed sale to Regeneron ...

Regeneron's new antibody drug, Lynozyfic, shows promise in eradicating residual multiple myeloma without the need for bone marrow transplants, according to a small mid-stage trial. The treatment ...

After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...

Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, ...

Regeneron released new early data on two of its blood cancer drugs at ASH, aiming to expand treatment options for patients ...